SCHEMBL6981803

SCHEMBL6981803

CC(=O)N[C@@H](SCCNC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM10 O14672 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
ADAM17 P78536 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
TGM2 P21980 2/20 0.39
TGM6 O95932 1/20 0.39
F13A1 P00488 1/20 0.39
TGM1 P22735 1/20 0.39
DRD2 P14416 5/20 0.38
DRD4 P21917 5/20 0.38
DRD3 P35462 4/20 0.38
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
AKR1C3 P42330 1/20 0.36
MC4R P32245 1/20 0.36
MC5R P33032 1/20 0.36
MC3R P41968 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981807 0.83 SMN1; SMN2 (0.43) ADAM10MMP12MMP13ADAM17SMN1; SMN2
SCHEMBL6978355 0.77 GFER (0.55) SMN1; SMN2DRD2DRD4DRD3ALDH1A1
SCHEMBL6979020 0.77 SMN1; SMN2 (0.49) ADAM10MMP12MMP13ADAM17SMN1; SMN2
SCHEMBL6979028 0.77 SMN1; SMN2 (0.49) ADAM10MMP12MMP13ADAM17SMN1; SMN2
SCHEMBL6978349 0.77 GFER (0.55) SMN1; SMN2DRD2DRD4DRD3ALDH1A1
SCHEMBL6984615 0.77 KMT2A (0.51) SMN1; SMN2TGM2TGM6F13A1TGM1
SCHEMBL6978563 0.76 CCR1 (0.50) ADAM10MMP12MMP13ADAM17SMN1; SMN2
SCHEMBL6982389 0.76 TGM2 (0.47) SMN1; SMN2TGM2TGM6F13A1TGM1
SCHEMBL6985309 0.75 CAPN1 (0.54) SMN1; SMN2TGM2TGM6F13A1TGM1
SCHEMBL6978390 0.75 KMT2A (0.49) SMN1; SMN2DRD2DRD4DRD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed